#France #Pierre Fabre #AI Drug Discovery #XtalPi #Castres

Pierre Fabre and XtalPi: A Revolutionary Collaboration in Drug Discovery

In a significant move for the pharmaceutical industry, Pierre Fabre Laboratories and XtalPi Holdings Limited have announced a groundbreaking collaboration focused on leveraging artificial intelligence (AI) for drug discovery. This partnership, unveiled on November 9, 2026, aims to revolutionize the process of discovering innovative clinical candidates, particularly in oncology, dermatology, and rare diseases.

The Framework of the Collaboration

Under the terms of this collaboration, XtalPi will harness its integrated AI capabilities and robotic platform to design and propose novel small-molecule treatments targeting undisclosed biological aims. Meanwhile, Pierre Fabre will contribute its expertise in medical biology, preclinical research, translational research, and clinical development to select the most promising compounds. Furthermore, Pierre Fabre will be primarily responsible for subsequent clinical development and commercial strategies.

This partnership effectively brings together the strengths of both companies to tackle complex targets that have historically been difficult to address—reflecting a shared commitment to meet unmet medical needs while presenting considerable opportunities in innovative drug discovery.

For Pierre Fabre, this collaboration marks a strategic enhancement to its research and development roadmap, bolstering its drug discovery capabilities. It also supports XtalPi's objectives of applying AI and robotics in the field of drug discovery from scratch. Together, the companies aspire to accelerate the identification of clinical candidates across multiple research programs, particularly focused on oncology and potentially other therapeutic areas.

Insights from Leadership

Raymond Zheng, Head of Integrated Drug Discovery at XtalPi, expressed enthusiasm about the partnership, stating, "We are honored to collaborate with Pierre Fabre Laboratories, a renowned international pharmaceutical company. This partnership merges XtalPi's expertise in AI and robotics with Pierre Fabre's recognized therapeutic development acumen. We hope to deliver promising preclinical candidates to benefit patients with unmet medical needs."

Francesco Hofmann, head of Research and Development for the Medical Care division at Pierre Fabre, also highlighted the importance of this collaboration, noting, "Partnering with XtalPi to leverage AI expertise in accelerating the delivery of high-quality clinical candidates targeting multiple aims is a vital advantage to our R&D roadmap and discovery engine."

Financial Aspects of the Agreement

The agreement includes an initial payment, multiple milestone-related payments, and a share of profits from future successes; however, the specific financial terms have not been disclosed publicly. This multifaceted approach indicates a significant investment and commitment by both parties to the drug discovery process.

As they embark on this journey together, Pierre Fabre and XtalPi are set to make a notable impact on the pharmaceutical landscape, driven by a shared vision for innovation and improvement in patient care.

For more information, visit Pierre Fabre's official site or follow them on social media @LaboratoiresPierreFabre and @PierreFabreOncology.

Contact for media inquiries: Laure Bregeon-Sgandurra at [email protected]